World's first biosimilar MAb approved: infliximab in South Korea
This article was originally published in Scrip
Executive Summary
South Korea has granted the first approval worldwide to a biosimilar version of Johnson & Johnson/Merck & Co's blockbuster biologic Remicade (infliximab).